<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2024-9.4.8</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4947</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МОРФОЛОГИЯ, ФИЗИОЛОГИЯ И ПАТОФИЗИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MORPHOLOGY, PHYSIOLOGY AND PATHOPHYSIOLOGY</subject></subj-group></article-categories><title-group><article-title>Изменения уровня контрольных точек иммунного ответа у больных с различными формами аутоиммунного тиреоидита</article-title><trans-title-group xml:lang="en"><trans-title>Changes in the level of immune checkpoints in patients with various forms of autoimmune thyroiditis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-2361-688X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабинский</surname><given-names>В. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Babinsky</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабинский Владимир Владимирович – очный аспирант кафедры патологической физиологии</p><p>672000, г. Чита, ул. Горького, 39а</p><p> </p></bio><bio xml:lang="en"><p>Vladimir V. Babinsky – Postgraduat at the Department of Pathological Physiology </p><p>Gorkogo str. 39A, Chita 672000</p></bio><email xlink:type="simple">babinscky.vladimir@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Читинская государственная медицинская академия» Минздрава России</institution></aff><aff xml:lang="en"><institution>Chita State Medical Academy</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>09</month><year>2024</year></pub-date><volume>9</volume><issue>4</issue><fpage>69</fpage><lpage>74</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бабинский В.B., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Бабинский В.B.</copyright-holder><copyright-holder xml:lang="en">Babinsky V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4947">https://www.actabiomedica.ru/jour/article/view/4947</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Аутоиммунный тиреоидит (АИТ) поражает более 5 % мировой популяции.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Определение уровня молекул sPD-1, sPD-L1, sCTLA-4, sB7.2 у лиц, страдающих различными формами аутоиммунного тиреоидита. </p></sec><sec><title>Методы</title><p>Методы. В исследовании принял участие 31 человек в возрасте от 18 до 40 лет. Все обследуемые были распределены нами на четыре группы: I группа – здоровые (n = 10); II группа – носители антител к тиреопероксидазе (АТ к ТПО) (n = 11); III группа – лица с субклинической формой гипотиреоза при АИТ (n = 6); IV группа – лица с АИТ, осложнённым гипотиреозом, медикаментозно компенсированным (n = 4). Проводился забор венозной крови для определения уровня АТ к ТПО методом иммуноферментного анализа, концентрации тиреотропного гормона и свободного тироксина – методом иммунохемилюминесценции, уровней sPD-1, sPD-1L, sCTLA-4 и sB7.2 – методом проточной цитофлуориметрии. Статистическая обработка проводилась с использованием однофакторного дисперсионного анализа Краскела – Уолисса.</p></sec><sec><title>Результаты</title><p>Результаты. При сравнении уровня sPD-1L в I (54,1 (28,7; 67,6) pg/ml) и II (4,36 (2,36; 18,0) pg/ml) группах выявлено, что данный показатель снизился на 91,94 % (р = 0,001). При сравнении уровня sPD-1 в группе здоровых (16,6 (13,6; 37,2) pg/ml) и IV группе (7,28 (5,18; 11,1) pg/ml) зарегистрировано его снижение на 56,14 % (р = 0,001). Концентрация sВ7.2 снизилась на 65,03 % в группе II (16,4 (15,6; 32,7) pg/ml) по сравнению с контрольной (46,9 (39,3; 54,4) pg/ml) (р = 0,001). В группе III уровень sCTLA-4 составил 3,22 (3,06; 3,33) pg/ml и снизился на 88,66 % по сравнению с контрольной группой (р = 0,001).</p></sec><sec><title>Заключение</title><p>Заключение. При развитии АИТ снижается концентрация sPD-1, sPD-1L, sCTLA-4 и sB7.2.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Autoimmune thyroiditis (AIT) affects more than 5 % of the world’s population.</p></sec><sec><title>The aim</title><p>The aim. To determine the level of sPD-1, sPD-L1, sCTLA-4 and sB7.2 molecules in individuals suffering from various forms of autoimmune thyroiditis.</p></sec><sec><title>Methods</title><p>Methods. The study included 31 individuals aged 18 to 40 years. They were divided into four groups: group I – healthy individuals (n = 10); group II – carriers of antibodies to thyroid peroxidase (n = 11); group III – individuals with AIT accompanied with subclinical form of hypothyroidism (n = 6); group IV – individuals with AIT complicated by compensated hypothyroidism (n = 4). Venous blood was collected to determine the level of antibodies to thyroid peroxidase using enzyme immunoassay, the concentration of thyroid stimulating hormone and free thyroxine – using chemiluminescence immunoassay, and the levels of sPD-1, sPD-1L, sCTLA-4, and sB7.2 – using flow cytofluorometry. Statistical processing was performed using the Kruskal – Wallis one-way analysis of variance.</p></sec><sec><title>Results</title><p>Results. When comparing the level of sPD-1L in groups I (54.1 (28.7; 67.6) pg/ml) and II (4.36 (2.36; 18.0) pg/ml), the decreased in this indicator was 91.94 % (p = 0.001). When comparing the sPD-1 level in the group of healthy individuals (16.6 (13.6; 37.2) pg/ml) and group IV (7.28 (5.18; 11.1) pg/ml), werecorded a decrease of 56.14 % (p = 0.001). The sB7.2 concentration decreased by 65.03 % in group II (16.4 (15.6; 32.7) pg/ml) compared to the control group (46.9 (39.3; 54.4) pg/ml) (p = 0.001). In group III, the sCTLA-4 level was 3.22 (3.06; 3.33) pg/ml and decreased by 88.66% compared to the control group (p = 0.001).</p></sec><sec><title>Conclusion</title><p>Conclusion. The development of autoimmune thyroiditis is accompanied with the decrease in the concentration of sPD-1, sPD-1L, sCTLA-4 and sB7.2.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>контрольные точки иммунного ответа</kwd><kwd>аутоиммунный тиреоидит</kwd><kwd>PD-1</kwd><kwd>PD-1L</kwd><kwd>CTLA-4</kwd><kwd>B7.2</kwd><kwd>AIT</kwd><kwd>ТТГ</kwd><kwd>Т3св.</kwd><kwd>Т4св</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immune checkpoints</kwd><kwd>autoimmune thyroiditis</kwd><kwd>PD-1</kwd><kwd>PD-1L</kwd><kwd>CTLA-4</kwd><kwd>B7.2</kwd><kwd>AIT</kwd><kwd>thyroid stimulating hormone</kwd><kwd>free T3</kwd><kwd>free T4</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке ФГБОУ ВО «Читинская государственная медицинская академия» Минздрава России.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. Lancet. 2023; 401(10391): 1878-1890. doi: 10.1016/S 0140-6736(23)00457-9</mixed-citation><mixed-citation xml:lang="en">Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. Lancet. 2023; 401(10391): 1878-1890. doi: 10.1016/S 0140-6736(23)00457-9</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Строев Ю.И., Агафонов П.В., Коровин А.Е., Рябкова В.А., Соболевская П.А., Федоткина Т.В., и др. Медицинская география и экология аутоиммунного тироидита Хасимото и связанных с ним заболеваний. Российские биомедицинские исследования. 2022; 7(2): 69-90. doi: 10.56871/2889.2022.10.83.006</mixed-citation><mixed-citation xml:lang="en">Stroev YI, Agafonov PV, Korovin AE, Ryabkova VA, Sobolevskaya PA, Fedotkina TV, et al. Medical geography and ecology of autoimmune Hashimoto thyroiditis and related disorders. Russian Biomedical Research. 2022; 7(2): 69-90. (In Russ.). doi: 10.56871/2889.2022.10.83.006</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Weetman AP. An update on the pathogenesis of Hashimoto’s thyroiditis. J Endocrinol Invest. 2021; 44(5): 883-890. doi: 10.1007/s40618-020-01477-1</mixed-citation><mixed-citation xml:lang="en">Weetman AP. An update on the pathogenesis of Hashimoto’s thyroiditis. J Endocrinol Invest. 2021; 44(5): 883-890. doi: 10.1007/s40618-020-01477-1</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Герасимов Г.А., Фадеев В.В., Петунина Н.А, Александрова Г.Ф., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению аутоиммунного тиреоидита у взрослых. Проблемы эндокринологии. 2003; 49(6): 50-50. doi: 10.14341/probl11777</mixed-citation><mixed-citation xml:lang="en">Dedov II, Melnichenko GA, Gerasimov GA, Fadeev VV, Petunina NA, Aleksandrova GF, et al. Clinical recommendations of the Russian Association of Endocrinologists for the diagnosis and treatment of autoimmune thyroiditis in adults. Problems of Endocrinology. 2003; 49(6): 50-50. (In Russ.). doi: 10.14341/probl11777</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, et al. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol. 2020; 200(2): 141-154. doi: 10.1111/cei.13421</mixed-citation><mixed-citation xml:lang="en">Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, et al. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol. 2020; 200(2): 141-154. doi: 10.1111/cei.13421</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Álvarez-Sierra D, Marín-Sánchez A, Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, González Ó, et al. Analysis of the PD-1/ PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. 2019; 103: 102285. doi: 10.1016/j.jaut.2019.05.013</mixed-citation><mixed-citation xml:lang="en">Álvarez-Sierra D, Marín-Sánchez A, Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, González Ó, et al. Analysis of the PD-1/ PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. 2019; 103: 102285. doi: 10.1016/j.jaut.2019.05.013</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014; 20(4): 290-295. doi: 10.1097/PPO.0000000000000056</mixed-citation><mixed-citation xml:lang="en">Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014; 20(4): 290-295. doi: 10.1097/PPO.0000000000000056</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Aprilia A, Handono K, Sujuti H, Sabarudin A, Winaris N. sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence. Immun Ageing. 2024; 21(1): 9. doi: 10.1186/s12979-023-00405-0</mixed-citation><mixed-citation xml:lang="en">Aprilia A, Handono K, Sujuti H, Sabarudin A, Winaris N. sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence. Immun Ageing. 2024; 21(1): 9. doi: 10.1186/s12979-023-00405-0</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Simone R, Pesce G, Antola P, Rumbullaku M, Bagnasco M, Bizzaro N, et al. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int. 2014; 2014: 215763. doi: 10.1155/2014/215763</mixed-citation><mixed-citation xml:lang="en">Simone R, Pesce G, Antola P, Rumbullaku M, Bagnasco M, Bizzaro N, et al. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int. 2014; 2014: 215763. doi: 10.1155/2014/215763</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer. Front Immunol. 2022; 13: 827921. doi: 10.3389/ fimmu.2022.827921</mixed-citation><mixed-citation xml:lang="en">Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer. Front Immunol. 2022; 13: 827921. doi: 10.3389/ fimmu.2022.827921</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
